Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2009 - 2017)

Vertex Pharmaceuticals has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $1.7 million in Q4 2017.

• For the quarter ending Q4 2017, Non-Current Deffered Revenue fell 73.97% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2017 stood at $1.7 million (down 73.97% YoY), and the FY2017 full-year result was $1.7 million, down 73.97% from the prior year.
• Non-Current Deffered Revenue for Q4 2017 stood at $1.7 million, down from $2.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $90.3 million in Q1 2013, with the low at $1.7 million in Q4 2017.
• Average Non-Current Deffered Revenue over 5 years is $28.1 million, with a median of $19.3 million recorded in 2015.
• Year-over-year, Non-Current Deffered Revenue declined 22.28% in 2013 and slumped 73.97% in 2017.
• Tracing VRTX's Non-Current Deffered Revenue over 5 years: stood at $49.5 million in 2013, then plunged by 43.78% to $27.8 million in 2014, then tumbled by 65.07% to $9.7 million in 2015, then slumped by 31.73% to $6.6 million in 2016, then sank by 73.97% to $1.7 million in 2017.
• The last three Non-Current Deffered Revenue figures came in at $1.7 million (Q4 2017), $2.9 million (Q3 2017), and $4.2 million (Q2 2017), per Business Quant data.

Peer Comparison